Liver, gallbladder, and bile ducts-pancreas (pancreas) (K70-K77; K80-K87).
- Hepatitis (inflammation of the liver), unspecified.
- Cirrhosis of the liver – connective tissue remodeling of the liver leading to functional impairment.
Neoplasms – tumor diseases (C00-D48).
- Benign (benign) tumors of the liver:
- (Cavernous) hepatic hemangioma (most common benign tumor of the liver; it is a vascular malformation in the liver) [usually uncomplicated course].
- Focal nodular hyperplasia (FNH; “benign proliferation of the liver”) [usually uncomplicated course].
- Hepatocellular adenoma (HCA; benign neoplasm of the liver; occurs mainly in women of childbearing age and is associated with the use of hormonal contraceptives (contraceptives), for example, the birth control pill)[if size ≥ 5 cm:
- Increase in complications (spontaneous rupture and bleeding (- 30% of cases).
- Risk of malignant transformation into hepatocellular carcinoma (HCC); this is dependent on sex, growth behavior, and histological/molecular subtype (β-HCA).
Measures:
- Women: Discontinuation of oral contraception and weight loss and follow-up.
- Men: resection due toincreased risk of degeneration.
- Acquired liver cysts, abscesses (encapsulated accumulation of pus) and hematomas (bruising).
- Cholangiocellular carcinoma (CCC) – epithelial neoplasia (neoplasm) spreading from the bile ducts; incidence (frequency of new cases): 2-4/100,000/year; second most common primary liver tumor after hepatocellular carcinoma; unfavorable prognosis due to anatomic location and early lymphatic and extrahepatic metastasis (formation of daughter tumors).
- Hepatoblastoma (HB); most common malignant (malignant) liver tumor in childhood; highest incidence in the first three years of life.
- Liver metastases (daughter tumors of malignant tumors in the liver); most commonly originate from primary tumors of the gastrointestinal tract; the most common primary tumor is colorectal carcinoma (colorectal cancer): 50% of these patients develop synchronous or metachronous liver metastases during the course of the disease
- Secondary liver tumors: Neuroendocrine tumors (NET); incidence: 5.3/100,000/year.
